Moorman Patricia G, Hamilton Robert J
Cancer Prevention, Detection and Control Research Program, Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Epidemiology. 2007 Mar;18(2):194-6. doi: 10.1097/01.ede.0000254699.31405.e2.
The relationship between statin use and cancer risk has been evaluated in numerous observational studies and as a secondary outcome in randomized controlled trials evaluating the effects of statins on cardiovascular outcomes. Although there are plausible biologic mechanisms to suggest that statins could inhibit cellular proliferation, the epidemiologic data do not show a consistent reduction in cancer risk among statin users. Despite the current lack of evidence for a chemopreventive effect, there are several methodologic considerations in the studies reported to date that prevent a definitive conclusion that statins do not reduce cancer risk. Given the widespread use of statins, continued monitoring of their risks and benefits is warranted.
他汀类药物的使用与癌症风险之间的关系已在众多观察性研究中进行了评估，并作为评估他汀类药物对心血管结局影响的随机对照试验的次要结局。尽管有合理的生物学机制表明他汀类药物可抑制细胞增殖，但流行病学数据并未显示他汀类药物使用者的癌症风险持续降低。尽管目前缺乏化学预防作用的证据，但迄今为止报告的研究中有几个方法学上的考虑因素，使得无法得出他汀类药物不会降低癌症风险的明确结论。鉴于他汀类药物的广泛使用，有必要继续监测其风险和益处。
